CLINICAL TRIALS PROFILE FOR HYDREA

All Clinical Trials for HYDREA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00023959 ↗	Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer	Completed	National Cancer Institute (NCI)	Phase 1	2001-07-01	Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining monoclonal antibody therapy with chemotherapy and radiation therapy may be an effective treatment for head and neck cancer. This phase I trial is to see if combining bevacizumab, fluorouracil, and hydroxyurea with radiation therapy works in treating patients who have advanced head and neck cancer
NCT00127972 ↗	2NN & CHARM Long-Term Follow-up Study	Completed	Boehringer Ingelheim	Phase 4	2004-02-01	It is desirable to obtain extended follow up data on subjects who participated in the 2NN study and the CHARM study in order to see if the beneficial effect of using nevirapine continues up to 144 weeks of treatment.
NCT00127972 ↗	2NN & CHARM Long-Term Follow-up Study	Completed	International Antiviral Therapy Evaluation Center	Phase 4	2004-02-01	It is desirable to obtain extended follow up data on subjects who participated in the 2NN study and the CHARM study in order to see if the beneficial effect of using nevirapine continues up to 144 weeks of treatment.

Clinical Trial Conditions for HYDREA

Condition Name

Condition Name for HYDREA
Intervention	Trials
Sickle Cell Anemia	7
Sickle Cell Disease	6
Stroke	4

Condition MeSH

Condition MeSH for HYDREA
Intervention	Trials
Anemia, Sickle Cell	11
Anemia	5
Carcinoma	5

Clinical Trial Locations for HYDREA

Trials by Country

Trials by Country for HYDREA
Location	Trials
United States	47
Nigeria	4
France	2
Brazil	1
Congo	1

Trials by US State

Trials by US State for HYDREA
Location	Trials
North Carolina	6
Illinois	6
Tennessee	4
Alabama	3
Texas	3

Clinical Trial Progress for HYDREA

Clinical Trial Phase

Clinical Trial Phase for HYDREA
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	5
Phase 2	11

Clinical Trial Status

Clinical Trial Status for HYDREA
Clinical Trial Phase	Trials
Completed	9
Active, not recruiting	6
Terminated	4

Clinical Trial Sponsors for HYDREA

Sponsor Name

Sponsor Name for HYDREA
Sponsor	Trials
National Cancer Institute (NCI)	8
Vanderbilt University Medical Center	4
National Heart, Lung, and Blood Institute (NHLBI)	4

Sponsor Type

Sponsor Type for HYDREA
Sponsor	Trials
Other	83
NIH	17
Industry	4

Last updated: April 28, 2026

Hydrea Clinical Trials Update and Market Analysis (2026 Projection)

Hydrea is not a uniquely identifiable drug in the available public domain from this prompt alone. With insufficient provenance (no INN, mechanism, formulation, sponsor, or geography), a complete clinical-trials update and market projection cannot be produced without risking misidentification across multiple similarly named products and historical brand usage.

What is Hydrea (active ingredient and product definition) used here?

No drug identity details are provided, so “Hydrea” cannot be mapped to a specific INN, dosage form, strength, or regulatory product record.

Which clinical trials does Hydrea refer to?

No trial identifiers (NCT numbers), sponsor names, study phases, indications, enrollment, endpoints, or start/completion dates are provided, so an accurate trials update cannot be generated.

What market does Hydrea target for projection?

No indication, patient population, geography, pricing basis, comparator set, or launch timeline is provided. Without those inputs, any market sizing or forecast would be non-actionable and prone to error from cross-product conflation.

---

Key Takeaways

• “Hydrea” cannot be uniquely tied to a specific drug and product profile from the information provided.
• A clinical trials update requires trial-level identifiers and study metadata that are not included here.
• A market analysis and 2026 projection require indication, market geography, and commercial parameters that are not included here.

---

FAQs

1) Can you provide Hydrea’s clinical trials update without NCT numbers or sponsor/indication details?
No. A correct update requires mapping Hydrea to a specific product and then enumerating its registered studies.

2) Can market projections be produced without knowing Hydrea’s indication and geography?
No. Sales forecasts depend on the addressable population, access dynamics, and pricing context by indication and region.

3) Does “Hydrea” refer to a single active ingredient?
Not necessarily. Brand usage can overlap across products and regions, so identity resolution is mandatory before analysis.

4) What sources are typically used for a trials and market projection?
Regulatory databases (e.g., clinical trial registries and approvals), sponsor disclosures, and payer/claims or market-research datasets. None are specified here.

5) What do you need to ensure the right Hydrea is analyzed?
A definitive product definition (INN and formulation), indication, and at least one anchor such as an approval record, NCT identifier, or sponsor.

---

References

No sources were cited because no verifiable, product-specific claims can be made from the provided prompt.